Prevention of Venous Thromboembolism Disease in Emergency Departments (PREVENU)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2010 by University Hospital, Angers.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University Hospital, Angers
ClinicalTrials.gov Identifier:
NCT01212393
First received: September 29, 2010
Last updated: NA
Last verified: September 2010
History: No changes posted
  Purpose

The appropriate use of thromboprophylaxis in medical patients admitted to hospital can substantially reduce the overall burden of disease due to venous thromboembolism. However, the use of thromboprophylaxis in medical setting appears to be generally poor leaving at-risk patients unprotected.

We aim to analyse the incidence of symptomatic thromboembolic disease following hospitalisation in medical setting and the efficacy of a multicomponent prevention approach in emergency department including systematic evaluation of thrombosis risk factors and remembers of thrombophylaxis indications and modalities for acutely ill medical patients.

Design: cluster randomized interventional study - Observational study at patient level

Setting: 30 French emergency departments

Patients: Patients over 40 years old admitted in participating emergency departments and hospitalized for acute medical reasons.

Main judgment criteria: the rate of symptomatic thromboembolic events and severe haemorrhage during a formal 3-months follow-up after hospital admission in patients hospitalized at least 48 hours.


Condition Intervention
Quality of Health Care
Behavioral: reminders

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Prevention of Venous Thromboembolism Disease for Acutelly Ill Medical Patients Admitted to Hospital : Systematic Analysis of Thrombosis Risk Factors and Remember of Prevention Treatment Indications in Emergency Departments.

Resource links provided by NLM:


Further study details as provided by University Hospital, Angers:

Primary Outcome Measures:
  • Symptomatic venous thromboembolic events and severe haemorrhage [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]

    the rate of symptomatic venous thromboembolic events and severe haemorrhage during a formal 3-months follow-up after hospital admission in patients hospitalized at least 48 hours.

    All possible thromboembolic events, severe haemorrhages and deaths will be analysed by an adjudication committee blinded of group assignation. Sudden death without obvious cause according to the adjudication committee will be considered as possible fatal pulmonary embolism.



Secondary Outcome Measures:
  • Rate of symptomatic venous thromboembolic events [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
    - The rate of symptomatic venous thromboembolic events during a formal 3-months follow-up after hospital admission oin all included patients oin patients hospitalized at least 48 hours. oin patients hospitalized less than 48 hours

  • Rate of thromboembolic events [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
    - The rate of thromboembolic events oin patients who had an appropriate thromboprophylactic treatment oin patients who had an inappropriate thromboprophylactic treatment oin patients who had no thromboprophylactic treatment

  • rate of severe haemorrhage [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
    - The rate of severe haemorrhage oin patients who had an appropriate thromboprophylactic treatment oin patients who had an inappropriate thromboprophylactic treatment oin patients who had no thromboprophylactic treatment

  • appropriateness of thromboprophylaxis [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]

    - The appropriateness of thromboprophylaxis in the overall population and according to group assignation:

    oNumber of patients needing prevention treatment according to international recommendations and who have an appropriate treatment.

    oNumber of patients without indication of thromboprophylaxis and who do not receive a treatment



Biospecimen Retention:   None Retained

observational study at the patient level - cluster randomized study


Estimated Enrollment: 18000
Study Start Date: September 2009
Estimated Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Intervention group
reminders
Behavioral: reminders
In the intervention group, emergency departments will be provided with poster and pocket cards and, if possible, with a computer decision support system remembering venous thromboembolism prophylactic treatment.
current practice group
no intervention

Detailed Description:

Method:

At the end of an observational period of a week, centers will be randomized in two groups: intervention or current practice. In the intervention group, centers will be provided with poster and pocket cards and, if possible, with a computer decision support system remembering venous thromboembolism prophylactic treatment. We will propose no change in current practice in the other group.

Primary outcome: the rate of symptomatic venous thromboembolic events and severe haemorrhage during a formal 3-months follow-up after hospital admission in patients hospitalized at least 48 hours.

All possible thromboembolic events, severe haemorrhages and deaths will be analysed by an adjudication committee blinded of group assignation. Sudden death without obvious cause according to the adjudication committee will be considered as possible fatal pulmonary embolism.

Sample size: We calculated sample size on the basis of primary outcome. Assuming the participation of 30 centers (15 in each group), an intracluster correlation of 0.01, a rate of symptomatic thromboembolic events or severe haemorrhage of 5% in the current practice group, we need a sample of 16170 patients (8085 in each group) to detect a 1.5 percentage absolute difference between the 2 groups (3.5% in the intervention group) with a power of 80% and a significance level of 5%.

Considering a rate of patients hospitalized less than 48 hours around 5% and of lost of follow-up around 3%, we anticipated to include 16500 patients for the main analysis and 18000 patients for the overall study.

Secondary outcomes:

  • The appropriateness of thromboprophylaxis in the overall population and according to group assignation:

    • Number of patients needing prevention treatment according to international recommendations and who have an appropriate treatment.
    • Number of patients without indication of thromboprophylaxis and who do not receive a treatment
  • The rate of symptomatic venous thromboembolic events during a formal 3-months follow-up after hospital admission

    • in all included patients
    • in patients hospitalized at least 48 hours.
    • inpatients hospitalized less than 48 hours
  • The rate of thromboembolic events

    • in patients who had an appropriate thromboprophylactic treatment
    • in patients who had an inappropriate thromboprophylactic treatment
    • in patients who had no thromboprophylactic treatment
  • The rate of severe haemorrhage

    • in patients who had an appropriate thromboprophylactic treatment
    • in patients who had an inappropriate thromboprophylactic treatment
    • in patients who had no thromboprophylactic treatment
  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Eligible centers: Emergency departments previously implicated in research on venous thromboembolism.

Eligible patients: patients over 40 years old admitted in participating emergency departments for non traumatic reason

Criteria

Inclusion Criteria:

  • age over 40 years
  • Emergency department admission for non-traumatic reason
  • Hospitalization in medical setting

Exclusion Criteria:

  • patients less than 40 years old
  • patients hospitalized in a facility which doesn't participate to the study
  • 3 months follow-up not possible
  • patients refusing that their personal data are used for medical research
  • patients refusing to be reach for the 3 months follow-up
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01212393

Contacts
Contact: Pierre-Marie ROY, MD 00-2-41-35-37-18 pmroy@chu-angers.fr

Locations
France
UH Agen Recruiting
Agen, France
Contact: Albane Buan, MD            
Principal Investigator: Albane Buan, MD            
H Argenteuil Recruiting
Argenteuil, France, 95107
Contact: Catherine Legall, MD     00-1-34-23-24-25     catherine.legall@ch-argenteuil.fr    
Principal Investigator: Catherine Legall, MD            
UH Besançon Recruiting
Besançon, France, 25000
Contact: Mohamed Hachelaf, MD     00-3-81-66-88-29     mhachelaf@chu-besancon.fr    
Principal Investigator: Mohamed Hachelaf, MD            
H Bethune Recruiting
Bethune, France, 62408
Contact: Alain-Eric Dubart, MD     00-3-21-64-44-44     adubart@ch-bethune.fr    
Principal Investigator: Alain-Eric Dubart, MD            
H Bobigny Recruiting
Bobigny, France
Contact: Adnet, MD, PhD            
Principal Investigator: Adnet, MD, PhD            
UH Ambroise Pare Recruiting
Boulogne Billancourt, France, 92100
Contact: David Elkharrat, MD     00-1-49-09-55-17     david.elkharrat@apr.ap-hop.fr    
Principal Investigator: David Elkharrat, MD            
Sub-Investigator: Laurence Arrouy, MD            
Sub-Investigator: Caroline Guyot, MD            
UH Brest Recruiting
Brest, France
Contact: Legal, MD            
Principal Investigator: Legal, MD            
Sub-Investigator: Mottier, MD            
H Chateauroux Recruiting
Chateauroux, France, 36019
Contact: Guillem Bouilleau, MD     00-2-54-22-88-88     guillem.bouilleau@ch-chateauroux.fr    
Principal Investigator: Guillem Bouilleau, MD            
H Clermont Ferrand Recruiting
Clermont Ferrand, France
Contact: Mustafa Fares, MD            
Principal Investigator: Mustafa Fares, MD            
Sub-Investigator: Jeannot Schmidt, MD, PhD            
H Compiegne Recruiting
Compiegne, France, 60200
Contact: Patrick Miroux, MD     00-3-44-23-63-88     patrick_miroux@yahoo.fr    
Principal Investigator: Patrick Miroux, MD            
UH Dijon Recruiting
Dijon, France, 21033
Contact: Didier Honnart, MD     00-3-80-29-37-46     didier.honnart@chu-dijon.fr    
Principal Investigator: Didier Honnart, MD            
UH Grenoble Recruiting
Grenoble, France, 38043
Contact: Françoise Carpentier, MD     00-4-76-76-59-31     fcarpentier@chu-grenoble.fr    
Principal Investigator: Françoise Carpentier, MD            
Sub-Investigator: Claire Arasomohano, MD            
UH La Reunion Recruiting
La Reunion, France
Contact: frederic Stakowski, MD            
Principal Investigator: frederic Stakowski, MD            
UH Marseille Recruiting
Marseille, France
Contact: Patrick Gerbeau, MD, PhD            
Principal Investigator: Patrick Gerbeau, MD, PhD            
UH Metz Thionville Recruiting
Metz, France
Contact: François Braun, MD            
Principal Investigator: François Braun, MD            
UH Nantes Recruiting
Nantes, France, 44100
Contact: Dominique Elkourri, MD         dominique.elkourri@chu-nantes.fr    
Principal Investigator: Dominique Elkourri, MD            
UH Nimes Recruiting
Nimes, France
Contact: Jean Flechet, MD            
Principal Investigator: Jean Flechet, MD            
Sub-Investigator: Jean-Yves Lefrant, MD, PhD            
UH Bichat Recruiting
Paris, France
Contact: Enrique Casalino, MD, PhD            
Principal Investigator: Enrique Casalino, MD, PhD            
UH Hotel Dieu Recruiting
Paris, France
Contact: Florence Dumas, MD            
Principal Investigator: Florence Dumas, MD            
Sub-Investigator: Nathalie Delormes, MD            
H Cochin Recruiting
Paris, France
Contact: Yann-Eric Claessens, MD,PhD            
Principal Investigator: Yann-Eric Claessens, MD,PhD            
UH la pitié salpetriere Recruiting
Paris, France, 75651
Contact: Pierre Hausfater, MD     00-1-42-17-72-68     pierre.hausfater@psl.ap-hop-paris.fr    
Principal Investigator: Pierre Hausfater, MD            
UH Poitiers Recruiting
Poitiers, France
Contact: Fatima Rayeh, MD            
Principal Investigator: Fatima Rayeh, MD            
UH Rennes Recruiting
Rennes, France
Contact: Jacques Bouget, MD, PhD            
Principal Investigator: Jacques Bouget, MD, PhD            
Sponsors and Collaborators
University Hospital, Angers
Investigators
Principal Investigator: Pierre-Marie ROY, MD, PhD UH Angers
  More Information

No publications provided

Responsible Party: ROY Pierre-Marie, University Hospital, Angers
ClinicalTrials.gov Identifier: NCT01212393     History of Changes
Other Study ID Numbers: PHRC 2008-02
Study First Received: September 29, 2010
Last Updated: September 29, 2010
Health Authority: France: Institutional Ethical Committee

Keywords provided by University Hospital, Angers:
venous thromboembolism disease
emergency
prevention
thromboprophylaxis
medical
hosptitalization
health care risks

Additional relevant MeSH terms:
Emergencies
Thromboembolism
Venous Thromboembolism
Venous Thrombosis
Disease Attributes
Pathologic Processes
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Thrombosis

ClinicalTrials.gov processed this record on May 21, 2013